SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-016637
Filing Date
2022-08-11
Accepted
2022-08-11 07:13:02
Documents
81
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-20220630.htm   iXBRL 10-Q 2656353
2 EX-31.1 fnch-ex31_1.htm EX-31.1 21272
3 EX-31.2 fnch-ex31_2.htm EX-31.2 21577
4 EX-32.1 fnch-ex32_1.htm EX-32.1 22358
  Complete submission text file 0000950170-22-016637.txt   9933125

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fnch-20220630_def.xml EX-101.DEF 262503
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20220630.xsd EX-101.SCH 74302
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fnch-20220630_cal.xml EX-101.CAL 50216
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20220630_pre.xml EX-101.PRE 429320
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20220630_lab.xml EX-101.LAB 593737
75 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20220630_htm.xml XML 1796947
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 221153659
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences